Ranitidine, often called by the brand name Zantac, is an antacid and antihistamine that was commonly used to treat and prevent heartburn, stomach ulcers, gastroesophageal reflux disease (GERD), and other conditions that cause excess stomach acid.
On April 1, 2020, the Food and Drug Administration (FDA) issued a recall requesting that all manufacturers immediately withdraw prescription and over-the-counter (OTC) Zantac products due to excess levels of the potentially cancer-causing ingredient N-nitrosodimethylamine, or NDMA. The FDA has advised consumers to stop taking any Zantac tablets or liquid medications.
File Your Zantac Claim with Pope McGlamry Attorneys
For decades, pharmaceutical manufacturers have promoted Zantac and its generic forms as being safe and effective for use against heartburn, making it the first pharmaceutical drug to reach $1 billion in sales. These manufacturers have concealed from the public that these drugs contain a well-known cancer-causing compound, the levels of which increase over time and when the drug is stored at higher-than-normal temperatures, as discovered by the FDA. Pope McGlamry wants to hold these companies accountable for the hundreds of thousands of Zantac users that eventually developed cancer.
Did you or a loved one develop cancer after prolonged use of heartburn and acid-reducing medications like Zantac? If so, you may be entitled to compensation. Pope McGlamry is a nationally recognized civil litigation firm with years of experience in litigating defective drug cases. We have the resources and knowledge to take on big pharmaceutical companies--and the understanding and compassion for clients who suffer. Contact our experienced product liability attorneys to receive a free case evaluation and discuss your options.